Bruker Corporation (BRKR) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $36.66 (-0.14%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 13, 2026 | Evie Koslosky | Goldman Sachs | $35.00 | -4.5% |
| Feb 13, 2026 | Luke Sergott | Barclays | $50.00 | +36.4% |
| Jan 5, 2026 | Subbu Nambi | Guggenheim | $53.00 | +44.6% |
| Dec 15, 2025 | Brandon Couillard | Wells Fargo | $55.00 | +50.0% |
| Aug 5, 2025 | Daniel Arias | Stifel Nicolaus | $40.00 | +9.1% |
| Aug 4, 2025 | Luke Sergott | Barclays | $43.00 | +17.3% |
| Dec 19, 2024 | Subbu Nambi | Guggenheim | $72.00 | +96.4% |
| Sep 23, 2024 | Patrick Donnelly | Citigroup | $80.00 | +118.2% |
| Aug 27, 2024 | Brandon Couillard | Wells Fargo | $78.00 | +112.8% |
| May 20, 2024 | Daniel Arias | Stifel Nicolaus | $77.00 | +110.0% |
| May 5, 2021 | Tycho Peterson | J.P. Morgan | $60.00 | +63.7% |
Top Analysts Covering BRKR
BRKR vs Sector & Market
| Metric | BRKR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.45 | 2.24 | 2.41 |
| Analyst Count | 20 | 8 | 18 |
| Target Upside | +42.2% | +1150.2% | +14.9% |
| P/E Ratio | -640.87 | 7.46 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3.57B | $3.58B | $3.62B | 9 |
| 2027-03-31 | $800M | $830M | $863M | 4 |
| 2027-06-30 | $856M | $888M | $923M | 3 |
| 2027-09-30 | $906M | $939M | $977M | 3 |
| 2027-12-31 | $1.04B | $1.08B | $1.13B | 3 |
| 2028-03-31 | $838M | $869M | $904M | 2 |
| 2028-06-30 | $886M | $919M | $956M | 5 |
| 2028-09-30 | $945M | $981M | $1.02B | 4 |
| 2028-12-31 | $1.09B | $1.13B | $1.18B | 4 |
| 2029-12-31 | $4.14B | $4.19B | $4.23B | 5 |
| 2030-12-31 | $4.19B | $4.24B | $4.28B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.09 | $2.11 | $2.12 | 7 |
| 2027-03-31 | $0.37 | $0.38 | $0.40 | 3 |
| 2027-06-30 | $0.51 | $0.54 | $0.57 | 5 |
| 2027-09-30 | $0.61 | $0.64 | $0.67 | 3 |
| 2027-12-31 | $0.84 | $0.88 | $0.93 | 6 |
| 2028-03-31 | $0.48 | $0.50 | $0.53 | 4 |
| 2028-06-30 | $0.63 | $0.66 | $0.70 | 6 |
| 2028-09-30 | $0.70 | $0.74 | $0.78 | 4 |
| 2028-12-31 | $0.91 | $0.96 | $1.01 | 7 |
| 2029-12-31 | $3.09 | $3.14 | $3.18 | 1 |
| 2030-12-31 | $3.35 | $3.40 | $3.44 | 1 |
Frequently Asked Questions
What is the analyst consensus for BRKR?
The consensus among 20 analysts covering Bruker Corporation (BRKR) is Buy with an average price target of $52.13.
What is the highest price target for BRKR?
The highest price target for BRKR is $80.00, set by Patrick Donnelly at Citigroup on 2024-09-23.
What is the lowest price target for BRKR?
The lowest price target for BRKR is $35.00, set by Evie Koslosky at Goldman Sachs on 2026-02-13.
How many analysts cover BRKR?
20 analysts have issued ratings for Bruker Corporation in the past 12 months.
Is BRKR a buy or sell right now?
Based on 20 analyst ratings, BRKR has a consensus rating of Buy (2.45/5) with a +42.2% upside to the consensus target of $52.13.
What are the earnings estimates for BRKR?
Analysts estimate BRKR will report EPS of $2.11 for the period ending 2026-12-31, with revenue estimated at $3.58B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.